Recently, Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. announced that its subsidiary’s self-developed freeze-dried human rabies vaccine (produced using Vero cells) has officially received marketing authorization from China’s National Medical Products Administration (NMPA). Utilizing advanced Vero cell culture technology, the vaccine demonstrates high purity, strong safety profile, and excellent immunogenicity, making it suitable for post-exposure prophylaxis following potential rabies virus exposure. This approval marks a significant milestone in Baiyunshan’s vaccine development efforts, expanding its portfolio of biopharmaceutical products and enhancing China’s capacity to combat rabies. Rabies is nearly 100% fatal once symptoms appear, underscoring the critical importance of timely administration of high-quality vaccines after exposure. Baiyunshan stated it will accelerate the vaccine’s commercialization and market rollout to meet growing domestic public health demands and contribute to global rabies prevention and control.
近日，广州白云山医药集团股份有限公司宣布其子公司自主研发的冻干人用狂犬病疫苗（Vero细胞）正式获得国家药品监督管理局（NMPA）的注册批准。该疫苗采用先进的Vero细胞培养技术，具有高纯度、高安全性和良好免疫原性，适用于被狂犬病病毒暴露后的紧急预防接种。此次获批标志着白云山在疫苗研发领域取得重要突破，不仅丰富了公司生物制品产品线，也进一步提升了我国狂犬病防控能力。狂犬病一旦发病，致死率接近100%，因此暴露后及时接种高质量疫苗至关重要。白云山表示，将加快推进该疫苗的产业化和市场供应，以满足国内日益增长的公共卫生需求，并为全球狂犬病防控贡献力量。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/4937.html